Member Info for Chelsea11

What is also going on, is that the SP is well over 30% up YTD.

As I said following the loud bleating noises first thing……….

“Come on, its not even 9am yet in the UK and a handful of trades only”

Come on, its not even 9am yet in the UK and a handful of trades only.

“ This combination of innovative science, encouraging clinical data, and experienced leadership positions Scancell as a rising player in the cancer immunotherapy field”

The Proactive coverage yesterday was as comprehensive as we have seen it yet to date and suspect it will sink in for new PI’s.

Don’t think anyone has directly mentioned Modi so far today. Positive data from that may materially impact strategic direction.

Https://www.proactiveinvestors.co.uk/companies/news/1060830/scancell-trial-update-very-positive-says-broker-1060830.html

Https://www.proactiveinvestors.com/companies/news/1060808/scancell-s-chief-scientist-hails-excellent-melanoma-data-1060808.html

Yes Burble. The previously communicated full Cohort 3 data in H1 2025 has slipped to H2.

EE - from the link you yourself posted below, defending his nomination.

Kennedy’s baseless claims have included that Wi-Fi causes cancer and “leaky brain”; that school shootings are attributable to anti-depressants; that chemicals in water can lead to children becoming transgender; and that AIDS may not be caused by HIV. He’s also said that vaccines cause autism and fail to protect people from diseases.

Again, all I posted (it’s there in black & white), is that I saw nothing positive in his nomination from a Scancell perspective. Also that only time would tell if it had any negative impact on the business Scancell are in. Nothing more.

Laura - of course that’s all he’s said…….so far.

EE - the original point was clearly nothing to do with selling, or not selling. What I posted (look back if you need to) was that I saw nothing positive for Scancell in his appointment. That is all, nothing more.

“ Robert F Kennedy Jr, Trump's nominee to serve as the head of the US Department of Health and Human Services, is meanwhile facing backlash over his vaccine scepticism.

Shares in vaccine makers and healthcare firms around the world slid sharply on Friday, as investors reacted to the nomination of a campaigner who has vowed to crack down on “Big Pharma”.

The head of the American Public Health Association, which has a 25,000-strong membership of health professionals, told the BBC that Kennedy's criticism of immunisations had "already caused great damage in health in the country".

George C Benjamin added that Kennedy was "just absolutely the wrong guy for it".

Yes if you / anyone still believes there are positive elements for Scancell, that is allowed.

No EE, I haven’t sold. Just my opinion on his appointment doesn’t match yours. That’s allowed right? (and given Recs, I’m not alone either!)

Violin - mixed bag? Not for me in respect of vaccines.

I get that the US approach to health / regulation is very different to many other countries. However this is a guy who is about as anti-vax as you can get in his position. Check out the immediate market reaction to the main vaccine players following confirmation of his appointment by Trump.

Will it have a negative impact on Scancell? Who knows and only time will tell but I see nothing at all positive in his appointment from a Scancell perspective.

Democrat rep for California…….

"He’s a vaccine denier and a tin foil hat conspiracy theorist. He will destroy our public health infrastructure and our vaccine distribution systems,"

Not sure how that can be seen as a positive here.

And the Trial locations are not fully populated either. Nor does the messaging page work, so it would seem it’s a Beta version that we are looking at.

Chester -

Can’t now see SC88 (or SC27, or SC2811) in the pipeline.

WOW JB1.

Much more professional.

Perhaps those buying today, have read Cleaners “research” 😂

Hi Chester.

Dunno but it’s still listed in the mAb portfolio on the website.

SC129: specific for the sialyl-di-Lewisa glycan, a target for pancreatic cancer

SC134: specific for fucosyl GM1, a target for small cell lung cancer

SC88: specific for the Lewisacx glycan, a target for colorectal cancer

SC27: specific for the Lewisy glycan, a target for gastric cancer

SC2811: specific for SSEA4 on human and mouse T cells with stem-like properties – a target for any solid tumour

However that could be an administrative oversight I suppose.

Wasn’t it CT that stated something along the lines of “I know something that you don’t but will not be telling you what”. (About what is going on inside the Company).